Unknown

Dataset Information

Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy.


ABSTRACT:

Background

The optimal timing to initiate bevacizumab (BV) therapy for recurrent glioblastoma (GBM) is currently unclear. To address this issue, we examined progression-free survival (PFS) and survival time (ST) in a large retrospective cohort of GBM patients treated with BV at different recurrences.

Methods

We identified 468 primary GBM patients who underwent biopsy or surgery followed by radiation therapy and temozolomide (RT/TMZ), and then received BV. PFS and ST were compared between patients stratified by the recurrence that BV was initiated (upfront, first recurrence, second recurrence, or 3+ recurrences). We also examined the effect on PFS and ST of the addition of chemotherapy to BV. In a larger cohort of GBM patients, we determined overall treatment continuation rat

SUBMITTER: Piccioni DE 

PROVIDER: S-EPMC4022228 | biostudies-literature | 2014 Jun

REPOSITORIES: biostudies-literature